In a recent research report by Maximize Market Research, the Global Alzheimer’s Disease Diagnostic Market is expected to surpass US$ 5,647.50 Million by the year 2027, from US$ 2,154.68 Million in 2019.
Despite a huge decline in the sales of Grades during the initial phase of pandemic spread and lockdown restrictions all over the region, the market is observed to pick up a quick pace for registering a CAGR of almost more than 12.8%, during the tenure of 2019 – 2027.
The report published by Maximize encompasses the market dynamics, which could affect the market growth of white goods in the region, the Value – Chain Analysis, and the PORTER’s analysis for the white goods market at a global level.
The study is associated on the basis of major segments and further into sub-segments, by Therapeutics (Cholinesterase Inhibitors, NMDA Receptor Antagonists, and Other Therapeutics) and Diagnostics (Brain Imaging and CSF Test for Alzheimer’s Disease)) to forecast the market size by value; also includes the analysis of past market dynamics from 2016 – 2019, considering 2019 as the base year.
Lastly, the market research report provides a regional comparison and a complete country-level analysis for the latest trends, along with the major key players- Eli Lilly and Company, TauRx (Republic of Singapore), Alector LLC, Accera, Inc., Treventis Corporation, Neuro-Bio Ltd, Cognition Therapeutics Inc, Hoffmann-La Roche, Novartis AG, Merck & Co., Pfizer Inc., Allergan PLC, Daiichi Sankyo Co.
You can browse the market data Tables and Figures spread through a comprehensive research report and in-depth TOC on the “Global Alzheimer’s Disease Diagnostic Market.”
Contact:
MAXIMIZE MARKET RESEARCH PVT. LTD.
Omkar Heights,
ManikBaug, Vadgaon Bk,
Sinhagad Road, Pune – 411051,
Maharashtra, India.
+91 9607195908